Just months after a phase III trial miss for TNX-102 SL in fibromyalgia elevated post-traumatic stress disorder (PTSD) to the lead indication for the Tonix Pharmaceuticals Holding Corp. drug, it has secured FDA breakthrough status in the condition, which is often tied to military combat trauma.